Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIMES 3 insulin-combination therapy study of imeglimin
jRCT2080223790Phase 3Completed
- Sponsor
- Poxel SA
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Imeglimin + insulin with Placebo + insulin (2 arms). Primary endpoint: Change in HbA1c from baseline. Started Jan 2018; status: completed.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080223790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223790.